新加归脾合剂治疗特发性血小板减少性紫癜的实验研究

目的 在临床证实新加归脾合剂治疗特发性血小板减少性紫癜(idiopathic thrombocytopenic purpura, ITP)具有明显疗效基础上,试图通过ITP动物模型验证其疗效,为进一步探讨该方作用机理与新药研发奠定基础。方法 用免疫造模法建立小鼠ITP动物模型,并选择相应检测方法观察ITP小鼠外周血象、骨髓象与病理组织学以判定治疗效果。结果 新加归脾合剂具有明显提高ITP小鼠外周血小板数、促进巨核细胞向成熟方向分化效应,对于骨髓与脾脏组织病理学无明显影响。结论 新加归脾合剂对特发性减少性紫癜治疗有效、安全,可在临床推广应用。

Exprimental Study of Idiopathic Thrombocytopenic Purpura Treated with Xinjiaguipiheji

Objective Based on the clinical study, we want to confirm the effect of Xinjiaguipiheji by the animal model of ITP. Method We used the immunity method to set up the mice models of ITP. The peripheral blood, bone marrow and histological pathology of bone marrow were explored by exact methods to value the treatment effect. Result Xinjiaguipiheji can improve the amount of platelet and promote the mature of megakaryocyte of mice significantly. But it has no effect on histological pathology of spleen and bone marrow. Conclusion Xinjiaguipiheji is an effective and safe medicine in treating ITP. It can be used widely in clinic.